Resveratrol inhibits proliferation and migration through SIRT1 mediated post-translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells

Molecular Medicine Reports

Volumn 16, Issue 6, 2017, Pages 8037-8044

  Chai, Rongfei ^a   Fu, Huiling ^a   Zheng, Zhaodi ^a   Liu, Tingting ^a   Ji, Shuhua ^a   Li, Guorong ^a  

^a SHANDONG NORMAL UNIVERSITY   (China)

Author keywords

DLC1; PI3K AKT; Resveratrol; SIRT1

Indexed keywords

CASPASE 3; CASPASE 7; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RESVERATROL; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SELISISTAT; SIRTUIN 1; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BEL-7402 CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HEP-G2 CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; MTT ASSAY; PI3K/AKT SIGNALING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SMMC-7721 CELL LINE; TUMOR SUPPRESSOR GENE; TUNEL ASSAY; UPREGULATION; CELL MOTION; DRUG EFFECT; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STILBENES;

EID: 85032737310     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2017.7612     Document Type: Article

References (40)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576, 2007.
2. Hsieh TC and Wu JM: Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors 36:360-369, 2010.
3. Frazzi R, Valli R, Tamagnini I, Casali B, Latruffe N and Merli F: Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. Int J Cancer 132:1013-1021, 2013.
4. Li Y, Zhu W, Li J, Liu M and Wei M: Resveratrol suppresses the STAT3 signaling pathway and inhibits proliferation of high glucose-exposed HepG2 cells partly through SIRT1. Oncol Rep 30:2820-2828, 2013.
5. Fang Y and Nicholl MB: Sirtuin 1 in malignant transformation: Friend or foe? Cancer Lett 306:10-14, 2011.
6. Buhrmann C, Shayan P, Popper B, Goel A and Shakibaei M: Sirt1 is required for resveratrol-mediated chemopreventive effects in colorectal cancer cells. Nutrients 8:145, 2016.
7. Fu Z and Tindall DJ: FOXOs, cancer and regulation of apoptosis. Oncogene 27:2312-2319, 2008.
8. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59-71, 2005.
9. Liu MH, Lin XL, Li J, He J, Tan T P, Wu SJ, Yu S, Chen L, Liu J, Tian W, et al: Resveratrol induces apoptosis through modulation of the Akt/FoxO3a/Bim pathway in HepG2 cells. Mol Med Rep 13:1689-1694, 2016.
10. Shankar S, Chen Q and Srivastava RK: Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3:7, 2008.
11. Tzivion G, Dobson M and Ramakrishnan G: FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813:1938-1945, 2011.
12. Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M and Al-Kuraya KS: Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One 6:e24703, 2011.
13. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58:2196-2199, 1998.
14. Lahoz A and Hall A: DLC1: A significant GAP in the cancer genome. Genes Dev 22:1724-1730, 2008.
15. Scholz R P, Regner J, Theil A, Erlmann P, Holeiter G, Jähne R, Schmid S, Hausser A and Olayioye MA: DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J Cell Sci 122:92-102, 2009.
16. Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY and Ng IO: Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 65:8861-8868, 2005.
17. Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 23:1405-1411, 2004.
18. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ and Hajjar RJ: Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 99:6252-6256, 2002.
19. Brunet A, Sweeney LB, Sturgill JF, Chua K F, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et al: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011-2015, 2004.
20. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410-7425, 2005.
21. Zhao H, Ho PC, Lo YH, Espejo A, Bedford MT, Hung MC and Wang SC: Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS One 7:e29416, 2012.
22. Wu H, Liang X, Fang Y, Qin X, Zhang Y and Liu J: Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed Pharmacother 62:613-621, 2008.
23. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009.
24. Aziz MH, Nihal M, Fu VX, Jarrard DF and Ahmad N: Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 5:1335-1341, 2006.
25. Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol protects PC12 cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a pathway. Cell Mol Neurobiol 35:513-522, 2015.
26. Niquet J and Wasterlain CG: Bim, Bad and Bax: A deadly combination in epileptic seizures. J Clin Invest 113:960-962, 2004.
27. Kaushal GP, Kaushal V, Hong X and Shah SV: Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60:1726-1736, 2001.
28. Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417-435, 2004.
29. Yang Q, Wang B, Zang W, Wang X, Liu Z, Li W and Jia J: Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS One 8:e70627, 2013.
30. Chae HD and Broxmeyer HE: SIRT1 deficiency downregulates PTEN/JNK/FOXO1 pathway to block reactive oxygen species-induced apoptosis in mouse Embryonic stem cells. Stem Cells Dev 20:1277-1285, 2011.
31. Ikenoue T, Inoki K, Zhao B and Guan KL: PTEN acetylation modulates its interaction with PDZ domain. Cancer Res 68:6908-6912, 2008.
32. Wang G, Wang JJ, To TS, Zhao HF and Wang J: Role of SIRT1-mediated mitochondrial and Akt pathways in glioblastoma cell death induced by Cotinus coggygria flavonoid nanoliposomes. Int J Nanomedicine 10:5005-5023, 2015.
33. Zhou X, Thorgeirsson SS and Popescu NC: Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 23:1308-1313, 2004.
34. Li G, Du X, Vass WC, Papageorge AG, Lowy DR and Qian X: Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA 108:17129-17134, 2011.
35. Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG and Lowy DR: Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 104:9012-9017, 2007.
36. Maddox AS and Burridge K: RhoA is required for cortical retraction and rigidity during mitotic cell rounding. J Cell Biol 160:255-265, 2003.
37. Kim TY, Lee JW, Kim H P, Jong HS, Kim TY, Jung M and Bang YJ: DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 355:72-77, 2007.
38. Scholz RP, Gustafsson JO, Hoffmann P, Jaiswal M, Ahmadian MR, Eisler SA, Erlmann P, Schmid S, Hausser A and Olayioye MA: The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp Cell Res 317:496-503, 2011.
39. Ko FC, Chan LK, Sze KM, Yeung YS, Tse EY, Lu P, Yu MH, Ng IO and Yam JW: PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nat Commun 4:1618, 2013.
40. Hers I, Wherlock M, Homma Y, Yagisawa H and Tavaré JM: Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells. J Biol Chem 281:4762-4770, 2006.